Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

661
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
661
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

48
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
48

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same author

Antitumor efficacy and safety of locoregional [<sup>177</sup>Lu]Lu-RM26 radionuclide therapy in glioblastoma.

European journal of nuclear medicine and molecular imaging·2026
Same author

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>225</sup>Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Building Sustainable Theranostics Programs: Operational Models, Access, and Equity.

PET clinics·2026
Same author

Theranostics: When Targeted Imaging Guides Targeted Therapy.

PET clinics·2026
Same author

From Feasibility to Durability: The Next Phase of Theranostics.

PET clinics·2026

Related Experiment Video

Updated: Apr 11, 2026

Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry
06:51

Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry

Published on: November 14, 2025

479

Companion Diagnostics and Molecular Imaging.

Ameya D Puranik1, Harshad R Kulkarni, Richard P Baum

  • 1From the Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), ENETS Center of Excellence, Zentralklinik Bad Berka, Germany.

Cancer Journal (Sudbury, Mass.)
|June 8, 2015
PubMed
Summary

Companion diagnostics (CDx) improve oncology drug development by guiding personalized treatment choices. Molecular imaging and theranostics are emerging tools enhancing patient care and safety.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging
08:04

Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging

Published on: April 14, 2011

25.4K

Related Experiment Videos

Last Updated: Apr 11, 2026

Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry
06:51

Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry

Published on: November 14, 2025

479
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging
08:04

Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging

Published on: April 14, 2011

25.4K

Area of Science:

  • Oncology
  • Translational Medicine
  • Medical Diagnostics

Background:

  • Companion diagnostics (CDx) are crucial for targeted cancer therapies, aiding oncologists in patient-specific treatment selection.
  • Regulatory bodies, like the US FDA, are developing strategies for CDx and drug-diagnostic co-development.
  • CDx assays are increasingly vital for patient care and safety in cancer treatment decisions.

Purpose of the Study:

  • To review the role and impact of companion diagnostics in drug development, particularly in oncology.
  • To explore the integration of molecular imaging into personalized medicine and drug development.
  • To discuss the emerging concept of theranostics in the context of companion diagnostics.

Main Methods:

  • Review of current literature and regulatory guidelines on companion diagnostics.
  • Analysis of the application of molecular imaging in drug development and personalized medicine.
  • Discussion of the principles and potential of theranostics.

Main Results:

  • Companion diagnostics are essential for selecting appropriate targeted therapies in oncology.
  • Molecular imaging offers a way to visualize biological targets at the genetic and receptor levels.
  • Theranostics represents a novel approach combining diagnostics and therapeutics.

Conclusions:

  • Companion diagnostics are integral to modern oncology, enabling precision medicine.
  • Molecular imaging and theranostics are promising advancements for future cancer care.
  • The integration of diagnostics and therapeutics will likely shape the future of personalized medicine.